Plasma Acylcarnitines and Risk of Lower-extremity Functional Impairment in Older Adults: a Nested Case-control Study

Overview

Journal Sci Rep

Specialty Science

Date 2021 Feb 9

PMID 33558555

Citations 6

Authors

Francisco Felix Caballero

Ellen A Struijk

Alberto Lana

Antonio Buno

Fernando Rodriguez-Artalejo

Esther Lopez-Garcia

Affiliations

Soon will be listed here.

Abstract

Elevated concentrations of acylcarnitines have been associated with higher risk of obesity, type 2 diabetes and cardiovascular disease. The aim of the present study was to assess the association between L-carnitine and acylcarnitine profiles, and 2-year risk of incident lower-extremity functional impairment (LEFI). This case-control study is nested in the Seniors-ENRICA cohort of community-dwelling older adults, which included 43 incident cases of LEFI and 86 age- and sex- matched controls. LEFI was assessed with the Short Physical Performance Battery. Plasma L-carnitine and 28 acylcarnitine species were measured. After adjusting for potential confounders, medium-chain acylcarnitines levels were associated with 2-year incidence of LEFI [odds ratio per 1-SD increase: 1.69; 95% confidence interval: 1.08, 2.64; p = 0.02]. Similar results were observed for long-chain acylcarnitines [odds ratio per 1-SD increase: 1.70; 95% confidence interval: 1.03, 2.80; p = 0.04]. Stratified analyses showed a stronger association between medium- and long-chain acylcarnitines and incidence of LEFI among those with body mass index and energy intake below the median value. In conclusion, higher plasma concentrations of medium- and long-chain acylcarnitines were associated with higher risk of LEFI. Given the role of these molecules on mitochondrial transport of fatty acids, our results suggest that bioenergetics dysbalance contributes to LEFI.

Citing Articles

Carnitine Metabolite as a Potential Circulating Biomarker for Sarcopenia in Men.

Seo J, Koh J, Cho H, Kim H, Lee Y, Kim S Endocrinol Metab (Seoul). 2024; 40(1):93-102.

PMID: 39604802 PMC: 11898317. DOI: 10.3803/EnM.2024.2117.

Plasma metabolites and physical function in patients undergoing hemodialysis.

Moorthi R, Moe S, OConnell T, Dickinson S, Kalim S, Thadhani R Sci Rep. 2024; 14(1):8427.

PMID: 38600145 PMC: 11006868. DOI: 10.1038/s41598-024-58522-9.

Combined Plasma DHA-Containing Phosphatidylcholine PCaa C38:6 and Tetradecanoyl-Carnitine as an Early Biomarker for Assessing the Mortality Risk among Sarcopenic Patients.

Ho H, Chen Y, Lo C, Tang H, Chang S, Fan C Nutrients. 2024; 16(5).

PMID: 38474739 PMC: 10933763. DOI: 10.3390/nu16050611.

Plasma acylcarnitine in elderly Taiwanese: as biomarkers of possible sarcopenia and sarcopenia.

Lo C, Lin C, Fan C, Tang H, Liu H, Ho H BMC Geriatr. 2023; 23(1):769.

PMID: 37993772 PMC: 10666394. DOI: 10.1186/s12877-023-04485-x.

Sex differences in the human metabolome.

Costanzo M, Caterino M, Sotgiu G, Ruoppolo M, Franconi F, Campesi I Biol Sex Differ. 2022; 13(1):30.

PMID: 35706042 PMC: 9199320. DOI: 10.1186/s13293-022-00440-4.

References

Gonzalez-Freire M, Moaddel R, Sun K, Fabbri E, Zhang P, Khadeer M . Targeted Metabolomics Shows Low Plasma Lysophosphatidylcholine 18:2 Predicts Greater Decline of Gait Speed in Older Adults: The Baltimore Longitudinal Study of Aging. J Gerontol A Biol Sci Med Sci. 2018; 74(1):62-67. PMC: 6298185. DOI: 10.1093/gerona/gly100. View

Mihalik S, Goodpaster B, Kelley D, Chace D, Vockley J, Toledo F . Increased levels of plasma acylcarnitines in obesity and type 2 diabetes and identification of a marker of glucolipotoxicity. Obesity (Silver Spring). 2010; 18(9):1695-700. PMC: 3984458. DOI: 10.1038/oby.2009.510. View

Lum H, Sloane R, Huffman K, Kraus V, Thompson D, Kraus W . Plasma acylcarnitines are associated with physical performance in elderly men. J Gerontol A Biol Sci Med Sci. 2011; 66(5):548-53. PMC: 3074959. DOI: 10.1093/gerona/glr006. View

Garcia-Esquinas E, Guallar-Castillon P, Antonio Carnicero J, Buno A, Garcia-Garcia F, Rodriguez-Manas L . Serum uric acid concentrations and risk of frailty in older adults. Exp Gerontol. 2016; 82:160-5. DOI: 10.1016/j.exger.2016.07.002. View

Rebouche C . Kinetics, pharmacokinetics, and regulation of L-carnitine and acetyl-L-carnitine metabolism. Ann N Y Acad Sci. 2004; 1033:30-41. DOI: 10.1196/annals.1320.003. View

Studenski S, Perera S, Patel K, Rosano C, Faulkner K, Inzitari M . Gait speed and survival in older adults. JAMA. 2011; 305(1):50-8. PMC: 3080184. DOI: 10.1001/jama.2010.1923. View

Reuter S, Evans A . Carnitine and acylcarnitines: pharmacokinetic, pharmacological and clinical aspects. Clin Pharmacokinet. 2012; 51(9):553-72. DOI: 10.1007/BF03261931. View

Wang T, Larson M, Vasan R, Cheng S, Rhee E, McCabe E . Metabolite profiles and the risk of developing diabetes. Nat Med. 2011; 17(4):448-53. PMC: 3126616. DOI: 10.1038/nm.2307. View

Longo N, Frigeni M, Pasquali M . Carnitine transport and fatty acid oxidation. Biochim Biophys Acta. 2016; 1863(10):2422-35. PMC: 4967041. DOI: 10.1016/j.bbamcr.2016.01.023. View

10.

Murphy R, Moore S, Playdon M, Kritchevsky S, Newman A, Satterfield S . Metabolites Associated With Risk of Developing Mobility Disability in the Health, Aging and Body Composition Study. J Gerontol A Biol Sci Med Sci. 2017; 74(1):73-80. PMC: 6298186. DOI: 10.1093/gerona/glx233. View

11.

Benito S, Sanchez-Ortega A, Unceta N, Goicolea M, Barrio R . LC-QQQ-MS routine analysis method for new biomarker quantification in plasma aimed at early chronic kidney disease diagnosis. J Pharm Biomed Anal. 2019; 169:82-89. DOI: 10.1016/j.jpba.2019.02.042. View

12.

Malaguarnera M, Cammalleri L, Gargante M, Vacante M, Colonna V, Motta M . L-Carnitine treatment reduces severity of physical and mental fatigue and increases cognitive functions in centenarians: a randomized and controlled clinical trial. Am J Clin Nutr. 2007; 86(6):1738-44. DOI: 10.1093/ajcn/86.5.1738. View

13.

Guallar-Castillon P, Sagardui-Villamor J, Balboa-Castillo T, Sala-Vila A, Ariza Astolfi M, Sarrion Pelous M . Validity and reproducibility of a Spanish dietary history. PLoS One. 2014; 9(1):e86074. PMC: 3896441. DOI: 10.1371/journal.pone.0086074. View

14.

Guralnik J, Ferrucci L, Simonsick E, Salive M, Wallace R . Lower-extremity function in persons over the age of 70 years as a predictor of subsequent disability. N Engl J Med. 1995; 332(9):556-61. PMC: 9828188. DOI: 10.1056/NEJM199503023320902. View

15.

Guralnik J, Ferrucci L, Pieper C, Leveille S, Markides K, Ostir G . Lower extremity function and subsequent disability: consistency across studies, predictive models, and value of gait speed alone compared with the short physical performance battery. J Gerontol A Biol Sci Med Sci. 2000; 55(4):M221-31. DOI: 10.1093/gerona/55.4.m221. View

16.

Sun L, Liang L, Gao X, Zhang H, Yao P, Hu Y . Early Prediction of Developing Type 2 Diabetes by Plasma Acylcarnitines: A Population-Based Study. Diabetes Care. 2016; 39(9):1563-70. DOI: 10.2337/dc16-0232. View

17.

Menni C, Kastenmuller G, Petersen A, Bell J, Psatha M, Tsai P . Metabolomic markers reveal novel pathways of ageing and early development in human populations. Int J Epidemiol. 2013; 42(4):1111-9. PMC: 3781000. DOI: 10.1093/ije/dyt094. View

18.

Corona G, Polesel J, Fratino L, Miolo G, Rizzolio F, Crivellari D . Metabolomics biomarkers of frailty in elderly breast cancer patients. J Cell Physiol. 2014; 229(7):898-902. DOI: 10.1002/jcp.24520. View

19.

Papandreou C, Bullo M, Ruiz-Canela M, Dennis C, Deik A, Wang D . Plasma metabolites predict both insulin resistance and incident type 2 diabetes: a metabolomics approach within the Prevención con Dieta Mediterránea (PREDIMED) study. Am J Clin Nutr. 2019; 109(3):626-634. PMC: 7307433. DOI: 10.1093/ajcn/nqy262. View

20.

Fried L, Lee J, Shlipak M, Chertow G, Green C, Ding J . Chronic kidney disease and functional limitation in older people: health, aging and body composition study. J Am Geriatr Soc. 2006; 54(5):750-6. DOI: 10.1111/j.1532-5415.2006.00727.x. View